|Bausch + Lomb, of Laval, Quebec||Clearvisc||Dispersive ophthalmic viscosurgical device||For use as a surgical aid in ophthalmic anterior segment procedures including extraction of a cataract and implantation of an intraocular lens||Received U.S. FDA approval|
|Chemence Medical Inc., of Alpharetta, Ga.||Exofin fusion||Combines a self-adhering flexible mesh strip and a fast-curing 2-octyl cyanoacrylate topical adhesive||Closes and seals incisions while forming an immediate microbial barrier to protect against infections||Received 510(k) clearance from the U.S. FDA|
|Nuvasive Inc., of San Diego||Simplify||Cervical artificial disc||For 2-level cervical total disc replacement||Received U.S. FDA approval|
|Vitro Biopharma Inc., of Golden, Colo.||Allorx||Mesenchymal stem cells||Treatment of COVID-19 patients with acute respiratory distress syndrome||Received IND approval from the FDA for its phase I-IIa randomized, double-blinded, placebo-controlled study|
For more information about individual companies and/or products, see Cortellis.